Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death

Blood
Gro GausdalStein Ove Døskeland

Abstract

Anthracycline action has been thought to involve the neosynthesis of proapoptotic gene products and to therefore depend on protein synthesis for optimal effect. We found that inhibition of general, but not rapamycin-sensitive (cap-dependent), protein synthesis in the preapoptotic period enhanced anthracycline-induced acute myelogenous leukemia (AML) cell death, both in vitro and in several animal AML models. Pre-apoptotic anthracycline-exposed AML cells had altered translational specificity, with enhanced synthesis of a subset of proteins, including endoplasmatic reticulum chaperones. The altered translational specificity could be explained by perturbation (protein degradation, truncation, or dephosphorylation) of the cap-dependent translation initiation machinery and of proteins control-ing translation of specific mRNAs. We propose that judiciously timed inhibition of cap-independent translation is considered for combination therapy with anthracyclines in AML.

References

Apr 1, 1975·Cancer·A Lasser, A E Acosta
Apr 15, 1992·Biochemical Pharmacology·N S Thakkar, C S Potten
May 1, 1989·International Journal of Radiation Oncology, Biology, Physics·J A Bonner, T S Lawrence
Dec 1, 1994·International Journal of Immunopharmacology·A P MakrigiannisD W Hoskin
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·H B JefferiesG Thomas
Oct 1, 1995·Biological & Pharmaceutical Bulletin·S FurusawaK Sasaki
Nov 1, 1995·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·M RemachaJ P Ballesta
Apr 29, 1998·The Journal of Biological Chemistry·N J Richter-CookW C Merrick
May 18, 1999·Molecular and Cellular Biology·W T PuD E Clapham
May 21, 1999·European Journal of Biochemistry·P Bargis-SurgeyJ P Reboud
Aug 24, 1999·The Biochemical Journal·R HovlandS O Døskeland
Sep 9, 2000·The Journal of Biological Chemistry·C GernerR Schulte-Hermann
May 16, 2001·The Journal of Biological Chemistry·B ThiedeT Rudel
Jun 21, 2001·Proceedings of the National Academy of Sciences of the United States of America·T V PestovaC U Hellen
Jun 21, 2001·Proceedings of the National Academy of Sciences of the United States of America·B RaughtN Sonenberg
Jun 22, 2001·The Journal of Biological Chemistry·G W RogersW C Merrick
Jul 13, 2001·Nature·P W ReddienH R Horvitz
Aug 9, 2001·Blood·G Laurent, J P Jaffrézou
Apr 12, 2002·The Journal of Biological Chemistry·Annabelle GrolleauLaura Beretta
May 15, 2002·The International Journal of Biochemistry & Cell Biology·Marek Tchórzewski
Aug 20, 2002·Journal of Hematotherapy & Stem Cell Research·Bjørn Tore GjertsenØystein Bruserud
Sep 19, 2002·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Maria A OrtizF Javier Piedrafita
Nov 9, 2002·European Journal of Biochemistry·Gareth J Browne, Christopher G Proud
Mar 26, 2003·Cell Death and Differentiation·U FischerK Schulze-Osthoff
Sep 23, 2003·Current Opinion in Immunology·Richard Clark, Gillian M Griffiths
Dec 4, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G GattaUNKNOWN EUROCARE Working Group
Aug 28, 2004·EMBO Reports·Tatyana V PestovaChristopher U T Hellen
Oct 27, 2004·Apoptosis : an International Journal on Programmed Cell Death·F Debierre-Grockiego

❮ Previous
Next ❯

Citations

Jun 2, 2012·The Journal of Clinical Investigation·Yuanyuan RuanJianxin Gu
Jul 1, 2010·Genome Medicine·Sigrun M HjelleBjørn T Gjertsen
Oct 31, 2013·ELife·Arun P WiitaJames A Wells
Apr 22, 2014·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Lene MyhrenLars Herfindal
Mar 5, 2011·Biochemical and Biophysical Research Communications·Yuqing HaoJianxin Gu
Sep 18, 2010·Current Opinion in Cell Biology·Francis ImpensKris Gevaert
Nov 3, 2009·Trends in Biotechnology·Dieter DemonPeter Vandenabeele
May 19, 2011·Cell Biochemistry and Function·A WergelandJ Van Rooyen
Jan 9, 2010·Proteomics·Francis ImpensKris Gevaert
Feb 20, 2016·Expert Review of Molecular Diagnostics·Bjørn T GjertsenJörn Skavland
Aug 8, 2015·ChemMedChem·Alexander H SandtorvHans-René Bjørsvik
Jan 18, 2018·Journal of Enzyme Inhibition and Medicinal Chemistry·Anthony PrandinaFlorent Perret

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.